Compounds > taxane
Page last updated: 2024-08-02 06:55:59

taxane

Description

taxane: produced by Taxomyces andreanae [MeSH]

taxane : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID9548828
CHEBI ID36064
MeSH IDM0215357

Synonyms (12)

Synonym
1605-68-1
(4r,4ar,6s,9r,10s,12ar)-tetradecahydro-4,9,12a,13,13-pentamethyl-6,10-methanobenzocyclodecene
CHEBI:36064
(4r-(4alpha,4abeta,6alpha,9alpha,10alpha,12aalpha))-tetradecahydro-4,9,12a,13,13-pentamethyl-6,10-methanobenzocyclodecene
taxane
6,10-methanobenzocyclodecene, tetradecahydro-4,9,12a,13,13-pentamethyl-, (4r-(4alpha,4abeta,6alpha,9alpha,10alpha,12aalpha))-
6,10-methanobenzocyclodecene, tetradecahydro-4,9,12a,13,13-pentamethyl-, (4r,4ar,6s,9r,10s,12ar)-
bay59-8862
DKPFODGZWDEEBT-QFIAKTPHSA-N
DTXSID70936327
Q27116688
(1s,3r,4r,8s,11s,12r)-4,8,12,15,15-pentamethyltricyclo[9.3.1.03,8]pentadecane

Drug Classes (2)

ClassDescription
terpenoid fundamental parent
diterpeneA C20 terpene.

Research

Studies (1,239)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's44 (3.55)18.2507
2000's375 (30.27)29.6817
2010's613 (49.48)24.3611
2020's207 (16.71)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials210 (16.30%)5.53%
Reviews247 (19.18%)6.00%
Case Studies45 (3.49%)4.05%
Observational20 (1.55%)0.25%
Other766 (59.47%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
hopane
0
terpenoid fundamental parent;
triterpene		00low000000
pinane
0
carbobicyclic compound;
monoterpene;
terpenoid fundamental parent		plant metabolite00low000000
carane
0
carbobicyclic compound;
monoterpene;
terpenoid fundamental parent		00low000000
camphane
0
monoterpene;
terpenoid fundamental parent		00low000000
phorbols
0
diterpene;
terpenoid fundamental parent		00low000000
eudesmane
0
sesquiterpene;
terpenoid fundamental parent		00low000000
abietane
0
diterpene;
terpenoid fundamental parent		00low000000
pimarane
0
diterpene;
terpenoid fundamental parent		00low000000
guaiane
0
sesquiterpene;
terpenoid fundamental parent		00low000000
cadinane
0
sesquiterpene;
terpenoid fundamental parent		00low000000
labdane
0
diterpene;
terpenoid fundamental parent		00low000000
oleanane
0
terpenoid fundamental parent;
triterpene		00low000000
drimane
0
sesquiterpene;
terpenoid fundamental parent		00low000000
ursane
0
terpenoid fundamental parent;
triterpene		00low000000
halimane
0
diterpene;
terpenoid fundamental parent		00low000000
phytane
0
diterpene00low000000
cembrane
0
diterpene00low000000
cembrene a
0
cycloalkatriene;
diterpene;
macrocycle		animal metabolite;
bacterial metabolite;
coral metabolite		00low000000
axerophthene
0
diterpene;
polyene		00low000000
rhodojaponin iii
0
diterpene00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
aminolevulinic acid
1
4-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite		202220222.0low000001
adenine
1
6-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2002200222.0low000100
benzoic acid
1
benzoic acidsalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite		202020204.0low000010
1-butanol
1
alkyl alcohol;
primary alcohol;
short-chain primary fatty alcohol		human metabolite;
mouse metabolite;
protic solvent		2004200420.0low000100
carbamates
1
amino-acid anion201720177.0low000010
chlorine
1
halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite		202320231.0low000001
salicylic acid
1
monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite		201820186.0low000010
lactic acid
1
2-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite		201720177.0low000010
glyceraldehyde
1
aldotriosefundamental metabolite2003200321.0low000100
dalteparin
1
2012201212.0low100010
hydrogen
1
elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite		2011201113.0low000010
niacinamide
1
pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor		201720177.0low100010
nitroxyl
1
nitrogen oxoacid1997199727.0low001000
uracil
5
pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite		2001200521.4low200500
isopentenyl pyrophosphate
1
prenol phosphateantigen;
antioxidant;
epitope;
Escherichia coli metabolite;
mouse metabolite;
phosphoantigen		2003200321.0low000100
2,4-dichlorophenoxyacetic acid
1
chlorophenoxyacetic acid;
dichlorobenzene		agrochemical;
defoliant;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
environmental contaminant;
phenoxy herbicide;
synthetic auxin		2002200222.0low000100
alendronate
1
1,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor		2009200915.0low000100
anastrozole
3
nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor		2004201715.3low100210
bicalutamide
2
(trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol		2006201314.5low000110
verapamil
1
aromatic ether;
nitrile;
polyether;
tertiary amino compound		1998199826.0low001000
carmustine
1
N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent		2002200222.0low000100
celecoxib
2
organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug		2005201116.0low100110
chloroquine
1
aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug		202120213.0low100001
fluorouracil
109
nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic		1999202313.7low410349534
ifosfamide
3
ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic		2000200621.3low001200
ketoconazole
1
dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine		2010201014.0low000100
kinetin
1
6-aminopurines;
furans		cytokinin;
geroprotector		2002200222.0low000100
letrozole
2
nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor		1997201717.0low101010
nocodazole
1
aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes		antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator		2012201212.0low000010
mitoxantrone
3
dihydroxyanthraquinoneanalgesic;
antineoplastic agent		2002200520.7low000300
ondansetron
1
carbazoles2002200222.0low000100
oxonic acid
12
1,3,5-triazines;
monocarboxylic acid		2004201913.3low100750
suramin
1
naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug		2003200321.0low000100
tegafur
15
organohalogen compound;
pyrimidines		2002201914.8low1001050
temozolomide
3
imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug		1997201419.7low001110
thalidomide
4
phthalimides;
piperidones		2002201017.0low300400
mitomycin
4
mitomycinalkylating agent;
antineoplastic agent		2004201813.0low200220
prednisolone
1
11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic		2007200717.0low000100
floxuridine
2
nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent		2002200520.5low000200
prednisone
3
11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug		1998201219.0low001110
serine
1
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2014201410.0low100010
1,2-dipalmitoylphosphatidylcholine
1
2000200024.0low001000
phenylalanine
1
amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		201620168.0low000010
colchicine
5
alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen		2002202310.0low000221
cytarabine
1
beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent		1999199925.0low001000
asparagine
1
amino acid zwitterion;
asparagine;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		202220222.0low000001
medroxyprogesterone acetate
1
20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive		2005200519.0low000100
ethylene oxide
1
gas molecular entity;
oxacycle;
saturated organic heteromonocyclic parent		allergen;
mouse metabolite;
mutagen		2005200519.0low000100
carvone
1
botanical anti-fungal agent;
carvones		allergen202220222.0low000001
pyrroles
2
pyrrole;
secondary amine		2008201313.5low200110
furan
1
furans;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		carcinogenic agent;
hepatotoxic agent;
Maillard reaction product		2008200816.0low000100
thiophenes
2
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent1997201617.5low001010
quinazolines
18
azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines		1997202112.1low7014121
indazoles
1
indazole201620168.0low000010
cyclopentane
6
cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent2002201613.0low000240
oxazoles
1
1,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		202120213.0low000001
thiazoles
3
1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene		2000201911.7low101020
pyrazines
1
diazine;
pyrazines		Daphnia magna metabolite2014201410.0low000010
hydrazine
1
azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor2006200618.0low000100
azacitidine
2
N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent2007201413.5low000110
fluorobenzenes
1
monofluorobenzenesNMR chemical shift reference compound1997199727.0low001000
cyclooctanone
1
1997199727.0low001000
oxetane
3
oxetanes;
saturated organic heteromonocyclic parent		2005201016.0low000300
alpha-aminopyridine
1
201720177.0low000010
podophyllotoxin
1
furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator		2000200024.0low001000
malondialdehyde
1
dialdehydebiomarker201820186.0low000010
2,3,4,5,6-pentafluorophenol
1
1997199727.0low001000
deoxycytidine
107
pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		1996202216.6low4301260332
chlormequat
1
quaternary ammonium ionplant growth retardant2003200321.0low000100
vancomycin
1
glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite		202120213.0low000001
d-alpha tocopherol
3
alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite		202120222.3low100003
fluorescein
1
2-benzofurans;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
polyphenol;
xanthene dye		fluorescent dye;
radioopaque medium		2009200915.0low000100
doxifluridine
2
organofluorine compound;
pyrimidine 5'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
prodrug		2002200520.5low000200
mannose
1
D-aldohexose;
D-mannose;
mannopyranose		metabolite201520159.0low100010
streptomycin
1
antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor		202120213.0low000001
lutetium
4
d-block element atom;
lanthanoid atom		201920233.2low000022
platinum
42
elemental platinum;
nickel group element atom;
platinum group metal atom		200120239.2low90092310
actinium
1
actinoid atom;
f-block element atom;
scandium group element atom		202120213.0low000001
gadolinium
1
f-block element atom;
lanthanoid atom		201620168.0low000010
camptothecin
29
delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite		1997202117.4low11061391
sodium pyrophosphate
1
inorganic sodium saltchelator;
food emulsifier;
food thickening agent		2003200321.0low000100
razoxane
1
N-alkylpiperazine2010201014.0low000100
phenyl acetate
3
benzenes;
phenyl acetates		2012201410.7low000030
alkenes
5
2001202212.8low000221
alovudine
1
pyrimidine 2',3'-dideoxyribonucleoside2012201212.0low000010
paclitaxel
220
taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent		1993202313.7medium22036687937
etoposide
14
beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor		2000202112.1low501391
n-(2-hydroxypropyl)methacrylamide
1
2009200915.0low000100
epirubicin
22
aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor		2000202113.0low4017131
eniluracil
2
pyrimidone2001200222.5low200200
lovastatin
1
delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug		2003200321.0low000100
itraconazole
1
aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles		EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor		2014201410.0low000010
aromasil
1
17-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic		2010201014.0low000100
topotecan
7
pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor		2000200520.9low401600
gemcitabine
70
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic		1996202217.0low2301136212
duloxetine hydrochloride
2
duloxetine hydrochlorideantidepressant201920204.5low100020
irinotecan
25
carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug		1997201915.0low110211120
ibandronic acid
1
1997199727.0low001000
capecitabine
56
carbamate ester;
cytidines;
organofluorine compound		antimetabolite;
antineoplastic agent;
prodrug		1999202312.7low260123311
gallium nitrate
1
2000200024.0low001000
venlafaxine hydrochloride
1
hydrochloride201620168.0low000010
mevastatin
1
2-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite		2003200321.0low000100
1,2-distearoyllecithin
1
2000200024.0low001000
baccatin iii
7
acetate ester;
benzoate ester;
tetracyclic diterpenoid		plant metabolite1995202313.7low001231
tallimustine
1
1997199727.0low001000
2-methoxyestradiol
1
17beta-hydroxy steroid;
3-hydroxy steroid		angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite		2009200915.0low000100
triazoles
5
1,2,3-triazole1997201716.0low101220
fluorodeoxyglucose f18
3
2-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose		2012201510.3low100030
zoledronic acid
3
1,1-bis(phosphonic acid);
imidazoles		bone density conservation agent1997202115.7low001101
5-fluoropyrimidine
1
201920195.0low000010
nicotine
1
3-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic		201820186.0low000010
coronatine
1
N-acyl-amino acid201520159.0low000010
uftoral
3
2002200520.7low000300
fotemustine
1
N-nitrosoureas;
organic phosphonate;
organochlorine compound		2002200222.0low000100
parthenolide
1
germacranolide2006200618.0low000100
ecteinascidin 743
2
acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound		alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite		2005201812.5low100110
1-hexadecyl-2-acetyl-glycero-3-phosphocholine
1
2-acetyl-1-alkyl-sn-glycero-3-phosphocholineantihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent		2006200618.0low000100
n'-(2-chloroethyl)-n-(2-(methylsulfonyl)ethyl)-n'-nitrosourea
1
1997199727.0low001000
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
1
azamacrocyclechelator;
copper chelator		202220222.0low000001
gefitinib
4
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist		2002201815.5low100310
teloxantrone
1
1997199727.0low001000
methotrexate
22
dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent		2000202015.4low20210100
abiraterone
5
3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor		201520196.8low000050
docetaxel anhydrous
130
secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent		1994202311.6low12013306126
irofulven
1
cyclohexenones2002200222.0low000100
lonafarnib
2
4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamideantineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor		2005200519.0low100200
dx 8951
3
pyranoindolizinoquinoline2000200421.3low301200
sabarubicin
1
2005200519.0low100100
10-deacetylbaccatine iii
8
secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		1994202318.9medium002411
10-deacetyltaxol
2
201520178.0low000020
atrasentan
1
pyrrolidines2006200618.0low000100
2,2,6,6-tetramethylpiperidine-n-oxide-4-amino-4-carboxylic acid
1
aminoxyls;
piperidinemonocarboxylic acid		1997199727.0low001000
aminopterin
1
dicarboxylic acidEC 1.5.1.3 (dihydrofolate reductase) inhibitor;
mutagen		1997199727.0low001000
enzastaurin
1
indoles;
maleimides		2009200915.0low100100
erlotinib hydrochloride
1
hydrochloride;
terminal acetylenic compound		antineoplastic agent;
protein kinase inhibitor		2013201311.0low000010
fluoroquinacrine
1
2002200222.0medium000100
lapatinib
10
furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor		201120179.6low5000100
sorafenib
1
(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor		201720177.0low100010
lenalidomide
1
aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator		2010201014.0low100100
cholic acid
1
12alpha-hydroxy steroid;
3alpha-hydroxy steroid;
7alpha-hydroxy steroid;
bile acid;
C24-steroid;
trihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite		201720177.0low000010
nsc 83265
1
benzenoid aromatic compound2002200222.0low000100
estramustine
9
17beta-hydroxy steroid;
carbamate ester;
organochlorine compound		alkylating agent;
antineoplastic agent;
radiation protective agent		2001200720.3low200900
elesclomol
1
carbohydrazide;
thiocarbonyl compound		antineoplastic agent;
apoptosis inducer		2006200618.0low000100
u-104
1
202320231.0low000001
allocolchicine
1
2002200222.0low000100
bortezomib
2
amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor		201420197.5low000020
jib-04
1
201720177.0low000010
leupeptins
1
2011201113.0low000010
carboplatin
69
1995202311.8low140518379
n-acetylneuraminic acid
1
N-acetylneuraminic acidsantioxidant;
bacterial metabolite;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
human metabolite;
mouse metabolite		202020204.0low100010
lycoctonine
1
diterpenoid2012201212.0low000010
betadex
1
cyclodextrin2001200123.0low000100
geranylgeranyl pyrophosphate
1
geranylgeranyl diphosphatemouse metabolite2014201410.0low000010
epothilone b
2
epothilone;
epoxide		antineoplastic agent;
apoptosis inducer;
microtubule-stabilising agent		2000201019.0low001100
diethylstilbestrol
1
olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen		2013201311.0low000010
epothilone a
24
epothilone;
epoxide		antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator		2000201914.5low8011760
afimoxifene
1
phenols;
tertiary amino compound		antineoplastic agent;
estrogen receptor antagonist;
metabolite		201620168.0low000010
benzyloxycarbonylleucyl-leucyl-leucine aldehyde
1
amino aldehyde;
carbamate ester;
tripeptide		proteasome inhibitor2011201113.0low000010
bromochloroacetic acid
1
2-bromocarboxylic acid;
monocarboxylic acid;
organochlorine compound		201820186.0low000010
glycosides
1
2005200519.0low000100
chalcone
1
chalconeEC 3.2.1.1 (alpha-amylase) inhibitor202320231.0low000001
flavin-adenine dinucleotide
1
flavin adenine dinucleotide;
vitamin B2		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prosthetic group		202220222.0low000001
pyrophosphate
1
diphosphate ion2003200321.0low000100
sesquiterpenes
2
2002200620.0low000200
curcumin
1
aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger		2010201014.0low000100
tamoxifen
34
stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator		1994202315.7low50418102
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium
1
201920195.0low000010
lithium
2
alkali metal atom202320231.0low000002
zd 6474
1
aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine		antineoplastic agent;
tyrosine kinase inhibitor		2005200519.0low100100
ovalbumin
1
2002200222.0low000100
fh535
1
sulfonamide2014201410.0low000010
naphthoquinones
1
2012201212.0low100010
bilirubin
1
biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite		2002200222.0low100100
dinoprostone
1
prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic		2005200519.0low000100
dinoprost
1
monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite		201820186.0low000010
calcitriol
1
D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical		2003200321.0low000100
jasmonic acid
2
oxo monocarboxylic acidjasmonates;
plant metabolite		2002201615.0low000110
lutein
1
carotenolfood colouring;
plant metabolite		201820186.0low000010
maytansine
9
alpha-amino acid ester;
carbamate ester;
epoxide;
maytansinoid;
organic heterotetracyclic compound;
organochlorine compound		antimicrobial agent;
antimitotic;
antineoplastic agent;
plant metabolite;
tubulin modulator		201220197.7low700090
lafutidine
1
organic molecular entity2012201212.0low100010
dorzolamide
1
sulfonamide;
thiophenes		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor		201620168.0low000010
granisetron
1
aromatic amide;
indazoles		2002200222.0low000100
sirolimus
1
antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor		2001200123.0low000100
alvocidib
1
dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound		antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor		2012201212.0low000010
goserelin
2
organic molecular entity2004201813.0low000110
orantinib
1
2013201311.0low100010
su 11248
1
monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist		2008200816.0low100100
palbociclib
3
aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor		201920214.3low100021
gallium
1
boron group element atom2000200024.0low001000
dimyristoylphosphatidylcholine
1
1,2-diacyl-sn-glycero-3-phosphocholine;
phosphatidylcholine 28:0;
tetradecanoate ester		antigen;
mouse metabolite		2000200024.0low001000
cysteine
1
cysteiniumfundamental metabolite2002200222.0low000100
sarcodictyin a
1
2000200024.0medium001000
pregabalin
1
gamma-amino acidanticonvulsant;
calcium channel blocker		202020204.0low100010
apaziquone
1
indoles1997199727.0low001000
radium
1
alkaline earth metal atom201820186.0low000010
rhizoxin
1
1,3-oxazoles;
epoxide;
macrolide antibiotic		antimitotic;
antineoplastic agent;
metabolite		2002200222.0low000100
everolimus
1
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor		201520159.0low000010
phomactin a
1
2006200618.0low000100
ixabepilone
15
1,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent		2005201714.7low8001320
tanespimycin
1
1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor		2011201113.0low000010
edatrexate
1
glutamic acid derivative1997199727.0low001000
larotaxel
1
2008200816.0low100100
ac 7700
1
2014201410.0low100010
idn 5109
1
2000200024.0low001000
bms-275183
1
2003200321.0low000100
iniparib
1
carbonyl compound;
organohalogen compound		2012201212.0low000010
abiraterone acetate
1
pyridines;
sterol ester		antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor;
prodrug		201620168.0low000010
lenvatinib
1
aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist		202320231.0low000001
cabazitaxel
12
tetracyclic diterpenoidantineoplastic agent;
microtubule-stabilising agent		200820235.3low100156
idn 5390
1
2002200222.0low000100
g(m1) ganglioside
2
alpha-N-acetylneuraminosyl-(2->3)-[beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine;
sialotetraosylceramide		201920214.0low000011
taxinine
1
2003200321.0medium000100
halichondrin b
2
furopyran2009201213.5low200110
pazopanib
2
aminopyrimidine;
indazoles;
sulfonamide		angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist		201620234.5low000011
sepantronium
1
organic cation2012201212.0low100010
vinflunine
4
acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
semisynthetic derivative;
vinca alkaloid		antineoplastic agent2006201811.5low300220
er-086526
19
cyclic ketal;
cyclic ketone;
macrocycle;
polycyclic ether;
polyether;
primary amino compound		antineoplastic agent;
microtubule-destabilising agent		200920236.9low7001153
zampanolide
5
201220189.2medium000050
tpi-287
1
202320231.0medium000001
trametinib
1
acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector		2014201410.0low000010
mln8054
1
benzazepine2013201311.0low000010
losartan potassium
1
2006200618.0low100100
sepharose
1
2002200222.0low000100
indocyanine green
1
1,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye		202020204.0low000010
n4-(2,2-dimethyl-3-oxo-4h-pyrid(1,4)oxazin-6-yl)-5-fluoro-n2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine
1
201920195.0low000010
acid phosphatase
1
2005200519.0low000100
discodermolide
1
201720177.0low000010
mdv 3100
8
(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound		androgen antagonist;
antineoplastic agent		201520216.2low000071
cytochrome c-t
1
2012201212.0low000010
phosphatidylcholines
1
1,2-diacyl-sn-glycero-3-phosphocholine2000200024.0low001000
technetium tc 99m sestamibi
1
2001200123.0low000100
olaparib
2
cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines		antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor		201220208.0low100020
methyl jasmonate
3
2012201410.7low000030
mln 8237
1
benzazepine202320231.0low000001
lde225
2
aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist		2012201411.0low000020
plx4032
1
aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor		2014201410.0low000010
piperidines
5
2005201216.2low300320
bryostatin 1
1
1997199727.0low001000
dabrafenib
1
1,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide		anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor		2014201410.0low000010
apatinib
1
201920195.0low100010
dicumarol
1
hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist		201620168.0low000010
s 1 (combination)
12
2004201913.3low100750
byl719
1
proline derivative201820186.0low100010
epidermal growth factor
1
2013201311.0low000010
transforming growth factor beta
1
201620168.0low000010
etirinotecan pegol
1
201520159.0low100010
gsk-j4
1
organonitrogen heterocyclic compound201720177.0low000010
cyclin d1
1
202320231.0low000001
hyaluronoglucosaminidase
1
2010201014.0low000100
cephalomannine
6
1997201516.3medium001410
vitamin b 12
2
2006201911.5low100110
aconitine
1
2012201212.0low000010
oblimersen
1
2005200519.0low100100
transforming growth factor alpha
1
2002200222.0low000100
psma-617
1
202320231.0low100001
nedaplatin
2
1997201219.5low001010
levoleucovorin
4
5-formyltetrahydrofolic acidantineoplastic agent;
metabolite		2001202314.2low200211
guanine
5
2-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2001201317.0low300320
guanosine
1
guanosines;
purines D-ribonucleoside		fundamental metabolite2003200321.0low000100
folic acid
2
folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient		2006201613.0low100110
dacarbazine
4
dacarbazine1997201420.2low001210
raltitrexed
1
N-acyl-amino acid1997199727.0low001000
pemetrexed
9
N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor		2001202111.7low300351
trypan blue
1
2002200222.0low000100
sta 9090
1
ring assembly;
triazoles		201720177.0low000010
flutax 2
1
2006200618.0low000100
pyrimidinones
1
2014201410.0low000010
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Ache0
5
201320234.8low300032
Acoustic Neurinoma, Bilateral0
1
201520159.0low000010
Acute Disease0
1
201820186.0low000010
Acute Pain0
3
201820233.7low000021
Acute Respiratory Distress Syndrome0
1
201520159.0low000010
Adenocarcinoma0
31
2000202212.7low12019201
Adenocarcinoma Of Kidney0
1
201720177.0low100010
Adenocarcinoma of Lung0
1
2014201410.0low000010
Adenocarcinoma, Basal Cell0
31
2000202212.7low12019201
Adenocarcinoma, Clear Cell0
6
2007201812.3low000420
Adenocarcinoma, Endometrioid0
2
2007200717.0low000200
Adenocarcinoma, Mucinous0
3
2007201614.0low000210
Adenocarcinoma, Papillary0
1
2010201014.0low000100
Adenocarcinoma, Scirrhous0
1
2005200519.0low000100
Adenocystic Carcinoma0
1
201620168.0low000010
Adverse Drug Event0
11
201120208.5low3000110
Age-Related Osteoporosis0
1
2012201212.0low000010
Allergic Reaction0
1
202020204.0low000010
Allergy, Drug0
8
200320237.8low000152
Allodynia0
1
201820186.0low000010
Alopecia0
14
200720226.1low3001112
Alopecia Cicatrisata0
14
200720226.1low3001112
Amenorrhea0
8
2005202011.0low200260
Androgen-Independent Prostatic Cancer0
34
201320234.9low50002113
Anemia0
8
2001201714.8low500530
Angiogenesis, Pathologic0
12
1998201914.3low201560
Angiosarcoma0
10
201120237.3low100082
Animal Mammary Carcinoma0
1
2000200024.0low001000
Anorexia0
1
2012201212.0low100010
Aprosodia0
1
2007200717.0low100100
Arthralgia0
3
2003201811.3low000120
Astrocytoma, Grade IV0
1
202320231.0low000001
Atypical Ductal Hyperplasia0
3
201620177.3low100030
B16 Melanoma0
2
1997200224.5low001100
Benign Meningeal Neoplasms0
1
2002200222.0low000100
Benign Neoplasms0
47
1993202311.6low30513236
Benign Neoplasms, Brain0
7
2009202110.3low200241
Bilateral Headache0
1
201720177.0low000010
Biliary Tract Cancer0
1
202220222.0low000001
Biliary Tract Neoplasms0
1
202220222.0low000001
Birth Weight0
1
2012201212.0low000010
Bladder Cancer0
8
2000201718.4low001520
Bladder Diseases0
1
2008200816.0low000100
Bleeding0
1
201720177.0low100010
Blood Clot0
1
201520159.0low000010
Blood Diseases0
3
2008201811.3low100120
Blood Poisoning0
2
2001201914.0low100110
Blood Pressure, High0
2
201720234.0low100011
Body Weight0
1
201620168.0low000010
Bone Cancer0
10
2002202113.6low300541
Bone Diseases, Metabolic0
1
2012201212.0low000010
Bone Neoplasms0
10
2002202113.6low300541
Brain Neoplasms0
7
2009202110.3low200241
Brain Vascular Disorders0
1
201620168.0low000010
Breast Cancer0
516
1994202311.3medium12801615928457
Breast Cancer, Male0
5
200620218.0low300131
Breast Carcinoma In Situ0
1
201720177.0low000010
Breast Neoplasms0
516
1994202311.3medium12801615928457
Breast Neoplasms, Male0
5
200620218.0low300131
Bronchial Neoplasms0
1
1998199826.0low001000
Cancer of Cervix0
7
2000201811.7low001150
Cancer of Colon0
6
1995201020.7low001500
Cancer of Endometrium0
7
200920238.7low100241
Cancer of Esophagus0
14
201120207.6low3000140
Cancer of Gastrointestinal Tract0
1
201820186.0low100010
Cancer of Head0
23
2001202012.9low50010130
Cancer of Larynx0
2
2007201214.5low100110
Cancer of Liver0
13
2002202315.6low3001021
Cancer of Lung0
95
1995202314.8low160943376
Cancer of Mediastinum0
1
2010201014.0low100100
Cancer of Mouth0
1
202320231.0low000001
Cancer of Nasopharynx0
2
201820214.5low000011
Cancer of Oropharnyx0
2
2007201911.0low100110
Cancer of Ovary0
125
1994202312.7low260843686
Cancer of Pancreas0
5
201320226.6low100041
Cancer of Pelvis0
2
2005200718.0low100200
Cancer of Penis0
2
201420169.0low000020
Cancer of Pharynx0
1
2001200123.0low000100
Cancer of Prostate0
59
1999202311.4low40123278
Cancer of Salivary Gland0
1
201620168.0low000010
Cancer of Skin0
11
2001202310.0low200272
Cancer of Stomach0
29
200420239.1low4007166
Cancer of the Fallopian Tube0
11
2000201615.9low401730
Cancer of the Urinary Tract0
5
2001201616.0low000320
Cancer of the Uterus0
5
2009201711.2low000230
Cancer of the Vagina0
1
2009200915.0low000100
Cancer, Embryonal0
1
2010201014.0low100100
Cancer, Radiation-Induced0
1
201820186.0low000010
Cancer, Second Primary0
5
200920235.8low000122
Carcinogenesis0
3
201520187.3low000030
Carcinoma0
19
1995202312.9low2024121
Carcinoma in Situ0
1
201720177.0low000010
Carcinoma, Adenoid Cystic0
1
201620168.0low000010
Carcinoma, Adenosquamous0
1
201620168.0low000010
Carcinoma, Anaplastic0
19
1995202312.9low2024121
Carcinoma, Colloid0
3
2007201614.0low000210
Carcinoma, Ductal0
1
2005200519.0low100100
Carcinoma, Ductal, Breast0
24
2002201712.0low3008160
Carcinoma, Ductal, Pancreatic0
1
201920195.0low000010
Carcinoma, Endometrioid0
2
2007200717.0low000200
Carcinoma, Epidermoid0
30
2001201913.0low80013170
Carcinoma, Intraductal, Noninfiltrating0
3
201620177.3low100030
Carcinoma, Intraepithelial0
1
201720177.0low000010
Carcinoma, Large Cell0
1
202020204.0low000010
Carcinoma, Lobular0
8
2002201713.0low300440
Carcinoma, Neuroendocrine0
1
202020204.0low000010
Carcinoma, Non-Small Cell Lung0
74
1995202313.9low130826337
Carcinoma, Non-Small-Cell Lung0
74
1995202313.9low130826337
Carcinoma, Oat Cell0
7
1999200821.6low002500
Carcinoma, Ovarian Epithelial0
21
201120229.4low2000201
Carcinoma, Pancreatic Ductal0
1
201920195.0low000010
Carcinoma, Papillary0
2
2009201313.0low000110
Carcinoma, Renal Cell0
1
201720177.0low100010
Carcinoma, Signet Ring Cell0
1
2013201311.0low000010
Carcinoma, Small Cell0
7
1999200821.6low002500
Carcinoma, Small Cell Lung0
4
2009201910.2low000130
Carcinoma, Squamous Cell0
30
2001201913.0low80013170
Carcinoma, Squamous Cell of Head and Neck0
4
201420216.2low100031
Carcinoma, Transitional Cell0
6
2000201616.7low001230
Carcinosarcoma0
1
201720177.0low000010
Cardiac Diseases0
1
2003200321.0low000100
Cardiac Failure0
4
201520205.5low000040
Cardiac Toxicity0
2
201820214.5low100011
Cardiomyopathy, Congestive0
1
201520159.0low000010
Cardiomyopathy, Dilated0
1
201520159.0low000010
Cardiotoxicity0
2
201820214.5low100011
Cardiovascular Diseases0
2
2007201911.0low100110
Cell Transformation, Neoplastic0
2
201720234.0low000011
Cells, Neoplasm Circulating0
7
200820199.6low000160
Central Hypothyroidism0
1
2010201014.0low000100
Central Retinal Edema, Cystoid0
4
201620224.8low000031
Cerebrovascular Disorders0
1
201620168.0low000010
Chemotherapy-Induced Acral Erythema0
8
201220208.4low600080
Chemotherapy-Induced Febrile Neutropenia0
3
201720205.7low200030
Cholangiocarcinoma0
1
202220222.0low000001
Cholangiocellular Carcinoma0
1
202220222.0low000001
Cholera Infantum0
1
2008200816.0low100100
Chromosomal Instability0
3
2007201314.3low000210
Chronic Pain0
1
201920195.0low000010
Chronic Primary Open Angle Glaucoma0
1
2000200024.0low001000
Cirrhosis0
2
201620168.0low100020
Cognition Disorders0
1
2002200222.0low000100
Cognitive Decline0
3
201620186.7low000030
Cognitive Dysfunction0
3
201620186.7low000030
Colonic Inertia0
1
2006200618.0low100100
Colonic Neoplasms0
6
1995201020.7low001500
Colorectal Cancer0
1
201720177.0low000010
Colorectal Neoplasms0
1
201720177.0low000010
Complication, Postoperative0
2
201620215.5low000011
Complications of Diabetes Mellitus0
1
201620168.0low000010
Complications, Neoplastic Pregnancy0
1
2012201212.0low000010
Congenital Familial Lymphedema0
7
201520216.3low000061
Constipation0
1
2006200618.0low100100
Contact Dermatitis0
1
2008200816.0low000100
Cranial Nerve II Diseases0
1
202220222.0low000001
Cystadenocarcinoma, Papillary0
1
2009200915.0low000100
Cystadenocarcinoma, Serous0
8
2007202012.8low000530
Cystadenoma, Serous0
1
201620168.0low000010
Deglutition Disorders0
1
2007200717.0low100100
Dehydration0
1
2004200420.0low000100
Dermatitis Medicamentosa0
1
201520159.0low100010
Dermatitis, Contact0
1
2008200816.0low000100
Dermatosclerosis0
2
2007201712.0low000110
Dermatoses0
1
2011201113.0low000010
Diabetes Mellitus0
1
2013201311.0low000010
Diarrhea0
11
200520229.6low900461
Diffuse Mixed Small and Large Cell Lymphoma0
1
1998199826.0low001000
Disease Exacerbation0
47
2000202313.4low210322193
Disease Models, Animal0
9
199920219.3low001161
Drug Hypersensitivity0
8
200320237.8low000152
Drug-Related Side Effects and Adverse Reactions0
11
201120208.5low3000110
Ductal Carcinoma0
1
2005200519.0low100100
Dysmyelopoietic Syndromes0
1
201820186.0low000010
Dysphagia0
1
2007200717.0low100100
Embolism, Pulmonary0
1
201920195.0low000010
Emesis0
7
2002202011.4low300340
Encephalopathy, Toxic0
9
201620234.8low100072
Endometrial Neoplasms0
7
200920238.7low100241
Enterocolitis, Necrotizing0
1
2006200618.0low000100
Epiphora0
2
202220231.5low000002
Epithelial Neoplasms0
19
2007201811.5low2003160
Epithelial Ovarian Cancer0
21
201120229.4low2000201
ER-Negative PR-Negative HER2-Negative Breast Cancer0
53
201320235.6low90003815
Esophageal Neoplasms0
14
201120207.6low3000140
Esophageal Squamous Cell Carcinoma0
2
201620206.0low000020
Exanthem0
1
201620168.0low000010
Exanthema0
1
201620168.0low000010
Experimental Lung Inflammation0
4
201520196.2low000040
Experimental Neoplasms0
3
2000201913.0low001020
Extra-Mammary Paget Disease0
1
202320231.0low000001
Extravasation of Contrast Media0
1
2010201014.0low000100
Fallopian Tube Neoplasms0
11
2000201615.9low401730
Fatigue0
6
2008202010.3low400240
Febrile Neutropenia0
1
202020204.0low000010
Female Genital Neoplasms0
10
200220238.6low500244
Fever0
5
2000201214.6low201040
Fibrosarcoma0
1
2002200222.0low000100
Fibrosis0
2
201620168.0low100020
Gangrene0
1
201720177.0low000010
Genetic Predisposition0
8
201220217.9low000071
Genital Neoplasms, Female0
10
200220238.6low500244
Genito-urinary Cancer0
1
202020204.0low000010
Germinoblastoma0
1
2006200618.0low100100
Glaucoma, Open-Angle0
1
2000200024.0low001000
Glioblastoma0
1
202320231.0low000001
Granulocytic Leukemia0
1
201820186.0low000010
Granuloma, Hodgkin0
1
201820186.0low000010
Gynandroblastoma0
1
201920195.0low000010
Hand-Foot Syndrome0
8
201220208.4low600080
Head and Neck Neoplasms0
23
2001202012.9low50010130
Headache0
1
201720177.0low000010
Heart Diseases0
1
2003200321.0low000100
Heart Failure0
4
201520205.5low000040
Hemangiosarcoma0
10
201120237.3low100082
Hematologic Diseases0
3
2008201811.3low100120
Hematuria0
1
201520159.0low000010
Hemorrhage0
1
201720177.0low100010
Hodgkin Disease0
1
201820186.0low000010
Hormone-Dependent Neoplasms0
7
2005201416.4low300610
HPV Infection0
1
201620168.0low000010
Hypersensitivity0
1
202020204.0low000010
Hypertension0
2
201720234.0low100011
Hypesthesia0
1
202320231.0low100001
Hypopharyngeal Cancer0
2
201820186.0low100020
Hypopharyngeal Neoplasms0
2
201820186.0low100020
Hypothyroidism0
1
2010201014.0low000100
Incontinentia Pigmenti Achromians0
1
201820186.0low000010
Infertility, Female0
1
201920195.0low000010
Inflammation0
6
1998202311.2low001221
Inflammatory Breast Cancer0
6
201220179.7low000060
Inflammatory Breast Neoplasms0
6
201220179.7low000060
Injuries, Radiation0
4
2010201610.5low200130
Innate Inflammatory Response0
6
1998202311.2low001221
Intestinal Obstruction0
1
2001200123.0low100100
Intradural-Extramedullary Spinal Cord Neoplasms0
1
2002200222.0low000100
Intraocular Pressure0
1
2000200024.0low001000
Invasiveness, Neoplasm0
14
2003201810.0low2002120
Joint Pain0
3
2003201811.3low000120
Lacrimal Apparatus Diseases0
2
202220231.5low000002
Laryngeal Neoplasms0
2
2007201214.5low100110
Lassitude0
6
2008202010.3low400240
LCIS, Lobular Carcinoma In Situ0
1
201720177.0low000010
Left Ventricular Dysfunction0
1
201620168.0low000010
Leiomyosarcoma0
1
2011201113.0low000010
Leiomyosarcoma, Epithelioid0
1
2011201113.0low000010
Leucocythaemia0
1
1998199826.0low001000
Leukemia0
1
1998199826.0low001000
Leukemia, Myeloid0
1
201820186.0low000010
Leukocytopenia0
6
2006201713.5low400330
Leukopenia0
6
2006201713.5low400330
Liver Diseases0
1
201920195.0low000010
Liver Dysfunction0
1
201920195.0low000010
Liver Neoplasms0
13
2002202315.6low3001021
Local Neoplasm Recurrence0
105
2001202310.5low270031659
Long Sleeper Syndrome0
1
202020204.0low000010
Low Bone Density0
1
2012201212.0low000010
Lung Adenocarcinoma0
1
2014201410.0low000010
Lung Neoplasms0
95
1995202314.8low160943376
Lupus Erythematosus, Cutaneous0
1
2008200816.0low000100
Lupus Erythematosus, Cutaneous, Subacute0
1
2008200816.0low000100
Lymph Node Metastasis0
45
1996202111.6low60213291
Lymphangitis0
1
2006200618.0low000100
Lymphedema0
7
201520216.3low000061
Lymphocytopenia0
1
2009200915.0low000100
Lymphoma0
1
2006200618.0low100100
Lymphoma, Non-Hodgkin0
1
1998199826.0low001000
Lymphopenia0
1
2009200915.0low000100
Macular Edema0
4
201620224.8low000031
Malignant Melanoma0
4
2002201418.0low000310
Mediastinal Neoplasms0
1
2010201014.0low100100
Melanoma0
4
2002201418.0low000310
Meningeal Neoplasms0
1
2002200222.0low000100
Menopause0
2
2006200618.0low000200
Metastase0
106
1998202214.0low440449503
Micrometastases, Neoplasm0
1
202120213.0low000001
Minimal Disease, Residual0
7
201220179.1low100070
Mouth Neoplasms0
1
202320231.0low000001
Mucositis0
1
2014201410.0low000010
Mucositis, Oral0
1
2007200717.0low100100
Multiple Primary Neoplasms0
1
201720177.0low000010
Muscle Pain0
2
201720186.5low000020
Musculoskeletal Diseases0
2
2010201312.5low000110
Myalgia0
2
201720186.5low000020
Myelodysplastic Syndromes0
1
201820186.0low000010
Nasal Diseases0
1
201820186.0low000010
Nasopharyngeal Carcinoma0
2
201820214.5low000011
Nasopharyngeal Neoplasms0
2
201820214.5low000011
Nausea0
10
2002202012.8low400550
Necrotizing Enterocolitis0
1
2006200618.0low000100
Neoplasm Metastasis0
106
1998202214.0low440449503
Neoplasm Metastasis, Unknown Primary0
2
2000200521.5low001100
Neoplasms0
47
1993202311.6low30513236
Neoplasms, Bronchial0
1
1998199826.0low001000
Neoplasms, Cystic, Mucinous, and Serous0
1
2014201410.0low000010
Neoplasms, Germ Cell and Embryonal0
1
2010201014.0low100100
Neoplasms, Pleural0
2
2009201313.0low000110
Nerve Pain0
7
201420206.1low200070
Nervous System Diseases0
2
2012201311.5low100020
Nervous System Disorders0
2
2012201311.5low100020
Neuralgia0
7
201420206.1low200070
Neurofibromatosis 20
1
201520159.0low000010
Neuropathy, Paraneoplastic0
1
2014201410.0low100010
Neutropenia0
23
2000201813.3low11018140
Obesity0
5
201320237.4low200041
Onycholysis0
1
201820186.0low000010
Optic Nerve Diseases0
1
202220222.0low000001
Oropharyngeal Neoplasms0
2
2007201911.0low100110
Orthopedic Disorders0
2
2010201312.5low000110
Osteoporosis0
1
2012201212.0low000010
Ovarian Neoplasms0
125
1994202312.7low260843686
Overweight0
1
201520159.0low100010
Paget Disease, Extramammary0
1
202320231.0low000001
Pain0
5
201320234.8low300032
Pain, Chronic0
1
201920195.0low000010
Pancreatic Neoplasms0
5
201320226.6low100041
Papillomavirus Infections0
1
201620168.0low000010
Penile Neoplasms0
2
201420169.0low000020
Peripheral Nerve Diseases0
63
200320235.2low160033525
Peripheral Nervous System Diseases0
63
200320235.2low160033525
Peritoneal Carcinomatosis0
16
2000202015.7low6011140
Peritoneal Neoplasms0
16
2000202015.7low6011140
Pharyngeal Neoplasms0
1
2001200123.0low000100
Pleural Effusion, Malignant0
2
2004200718.5low000200
Pneumonia0
4
201520196.2low000040
Polyploid0
1
2007200717.0low000100
Postoperative Complications0
2
201620215.5low000011
Postpartum Amenorrhea0
8
2005202011.0low200260
Pregnancy0
5
200920199.8low000140
Prostatic Neoplasms0
59
1999202311.4low40123278
Prostatic Neoplasms, Castration-Resistant0
34
201320234.9low50002113
Pulmonary Embolism0
1
201920195.0low000010
Pyrexia0
5
2000201214.6low201040
Recrudescence0
7
2007202110.9low100331
Respiratory Distress Syndrome0
1
201520159.0low000010
Response Evaluation Criteria in Solid Tumors0
3
201720214.7low100021
Restless Leg Syndrome0
1
2014201410.0low000010
Restless Legs Syndrome0
1
2014201410.0low000010
Salivary Gland Neoplasms0
1
201620168.0low000010
Scleroderma, Localized0
2
2007201712.0low000110
Scleroderma, Systemic0
2
201120218.0low000011
Sclerosis, Systemic0
2
201120218.0low000011
Sensation Disorders0
1
2007200717.0low000100
Sensitivity and Specificity0
6
2002202113.2low100231
Sepsis0
2
2001201914.0low100110
Sex Cord-Gonadal Stromal Tumors0
1
201920195.0low000010
Signet Ring Cell Carcinoma0
1
2013201311.0low000010
Sinus Tachycardia0
1
2007200717.0low100100
Skin Diseases0
1
2011201113.0low000010
Skin Neoplasms0
11
2001202310.0low200272
Sleep Wake Disorders0
1
202020204.0low000010
Small Cell Lung Carcinoma0
4
2009201910.2low000130
Soft Tissue Neoplasms0
1
2005200519.0low100100
Space Adaptation Syndrome0
1
2000200024.0low001000
Spinal Cord Neoplasms0
1
2002200222.0low000100
Squamous Cell Carcinoma of Head and Neck0
4
201420216.2low100031
Sterility, Female0
1
201920195.0low000010
Stomach Neoplasms0
29
200420239.1low4007166
Stomatitis0
1
2007200717.0low100100
Symptom Cluster0
2
2010201810.0low000110
Syndrome0
2
2010201810.0low000110
Taste Disorder, Anterior Tongue0
1
2013201311.0low000010
Tetraploid0
1
202320231.0low000001
Thrombocytopenia0
6
2000201714.3low401230
Thrombopenia0
6
2000201714.3low401230
Thrombosis0
1
201520159.0low000010
Triple Negative Breast Neoplasms0
53
201320235.6low90003815
Urinary Bladder Neoplasms0
8
2000201718.4low001520
Urogenital Neoplasms0
1
202020204.0low000010
Uterine Cervical Neoplasms0
7
2000201811.7low001150
Uterine Neoplasms0
5
2009201711.2low000230
Vaginal Neoplasms0
1
2009200915.0low000100
Ventricular Dysfunction, Left0
1
201620168.0low000010
Vomiting0
7
2002202011.4low300340
Weight Gain0
1
201720177.0low000010

Safety/Toxicity (52)

ArticleYear
Modulation of taxane binding to tubulin curved and straight conformations by systematic 3'N modification provides for improved microtubule binding, persistent cytotoxicity and in vivo potency.
European journal of medicinal chemistry, , Nov-05, Volume: 259		2023
Neurotoxicity induced by taxane-derived drugs: analysis of the FAERS database 2017-2021.
Expert opinion on drug safety, , Volume: 22, Issue:8
Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
JAMA ophthalmology, , 09-01, Volume: 140, Issue:9		2022
Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.
Clinical and translational science, , Volume: 15, Issue:10		2022
Serum Biomarkers for Chemotherapy Cardiotoxicity Risk Detection of Breast Cancer Patients.
Asian Pacific journal of cancer prevention : APJCP, , 10-01, Volume: 22, Issue:10		2021
A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer.
Clinical breast cancer, , Volume: 21, Issue:3		2021
Assessing taxane-associated adverse events using the FDA adverse event reporting system database.
Chinese medical journal, , Jun-01, Volume: 134, Issue:12		2021
The efficacy and safety of gemcitabine-based induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A meta-analysis.
Medicine, , Apr-09, Volume: 100, Issue:14		2021
Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis.
Oncology research and treatment, , Volume: 43, Issue:12		2020
Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses.
BMC cancer, , Jul-22, Volume: 20, Issue:1		2020
Predicting toxicity of platinum and taxane-based chemotherapy in older patients with gynecologic cancer.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, , Volume: 25, Issue:2
Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives.
British journal of pharmacology, , Volume: 177, Issue:14		2020
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.
Breast cancer research and treatment, , Volume: 180, Issue:3		2020
Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial.
Clinical drug investigation, , Volume: 40, Issue:3		2020
Perception of side effects associated with anticancer treatment in women with breast or ovarian cancer (KEM-GO-1): a prospective trial.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:8		2020
Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment.
Journal of the peripheral nervous system : JPNS, , Volume: 24 Suppl 2		2019
The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.
Journal of the National Cancer Institute, , 01-01, Volume: 112, Issue:1		2020
Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial.
Breast cancer research and treatment, , Volume: 175, Issue:3		2019
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Annals of oncology : official journal of the European Society for Medical Oncology, , 05-01, Volume: 30, Issue:5		2019
Evaluation of Prevention Interventions for Taxane-Induced Dermatologic Adverse Events: A Systematic Review.
JAMA dermatology, , 12-01, Volume: 154, Issue:12		2018
Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis.
Drug design, development and therapy, , Volume: 11		2017
Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Cancer chemotherapy and pharmacology, , Volume: 80, Issue:3		2017
Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis.
Scientific reports, , 07-13, Volume: 7, Issue:1		2017
Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.
Future oncology (London, England), , Volume: 13, Issue:11		2017
Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.
Thoracic cancer, , Volume: 8, Issue:3		2017
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Journal of the National Cancer Institute, , Volume: 108, Issue:10		2016
Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy.
Breast (Edinburgh, Scotland), , Volume: 29		2016
[Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a Meta-analysis of the efficacy and safety].
Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery, , Volume: 30, Issue:4		2016
The efficacy and safety of endostar combined with taxane-based regimens for HER-2-negative metastatic breast cancer patients.
Oncotarget, , May-24, Volume: 7, Issue:21		2016
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 07-01, Volume: 34, Issue:19		2016
[Efficacy and safety of cisplatin plus capecitabine for patients with metastatic triple negative breast cancer progressing after anthracycline and taxane treatment].
Zhonghua zhong liu za zhi [Chinese journal of oncology], , Volume: 37, Issue:12		2015
[Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes].
Zhonghua zhong liu za zhi [Chinese journal of oncology], , Volume: 37, Issue:10		2015
Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:5		2016
Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.
Cancer chemotherapy and pharmacology, , Volume: 76, Issue:4		2015
Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
BMC cancer, , May-21, Volume: 15		2015
Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.
Journal of the neurological sciences, , Feb-15, Volume: 349, Issue:1-2		2015
SNPs and taxane toxicity in breast cancer patients.
Pharmacogenomics, , Volume: 15, Issue:15		2014
Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Pharmacogenomics, , Volume: 15, Issue:12		2014
Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001).
European journal of cancer (Oxford, England : 1990), , Volume: 50, Issue:14		2014
Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer--a retrospective analysis of toxicity and outcomes.
Scottish medical journal, , Volume: 59, Issue:1		2014
Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Oct-15, Volume: 19, Issue:20		2013
Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.
PloS one, , Volume: 8, Issue:7		2013
Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.
Chinese medical journal, , Volume: 125, Issue:5		2012
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 22, Issue:3		2011
Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
Gynecologic oncology, , Volume: 106, Issue:2		2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Feb-20, Volume: 25, Issue:6		2007
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.
Applied immunohistochemistry & molecular morphology : AIMM, , Volume: 13, Issue:1		2005
Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).
Cancer, , Aug-15, Volume: 98, Issue:4		2003
Cardiotoxic effects of anthracycline-taxane combinations.
Expert opinion on drug safety, , Volume: 2, Issue:1		2003
An evaluation of toxicity of Taxus baccata Linn. (Talispatra) in experimental animals.
Journal of ethnopharmacology, , Volume: 79, Issue:1		2002
Taxanes: the genetic toxicity of paclitaxel and docetaxel in somatic cells of Drosophila melanogaster.
Mutagenesis, , Volume: 16, Issue:1		2001
Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
Toxicology and applied pharmacology, , Mar-01, Volume: 163, Issue:2		2000

Pharmacokinetics (8)

ArticleYear
Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study.
European journal of cancer (Oxford, England : 1990), , Volume: 139		2020
Pharmacokinetic synergy from the taxane extract of Taxus chinensis improves the bioavailability of paclitaxel.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , May-15, Volume: 22, Issue:5		2015
Effect of taxane-based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated by 3T MR.
NMR in biomedicine, , Volume: 26, Issue:12		2013
The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland.
Gynecologic oncology, , Volume: 115, Issue:2		2009
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy.
British journal of cancer, , Nov-06, Volume: 95, Issue:9		2006
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
AJR. American journal of roentgenology, , Volume: 184, Issue:6		2005
Taxanes: an overview of the pharmacokinetics and pharmacodynamics.
Urology, , Volume: 54, Issue:6A Suppl		1999
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Volume: 14, Issue:6		1996

Bioavailability (8)

ArticleYear
Role of Colloidal Drug Delivery Carriers in Taxane-mediated Chemotherapy: A Review.
Current pharmaceutical design, , Volume: 22, Issue:33		2016
Pharmacokinetic synergy from the taxane extract of Taxus chinensis improves the bioavailability of paclitaxel.
Phytomedicine : international journal of phytotherapy and phytopharmacology, , May-15, Volume: 22, Issue:5		2015
The discovery of BMS-275183: an orally efficacious novel taxane.
Bioorganic & medicinal chemistry, , Oct-01, Volume: 11, Issue:20		2003
Second generation taxanes: from the natural framework to the challenge of drug resistance.
Current medicinal chemistry. Anti-cancer agents, , Volume: 3, Issue:2		2003
Overcoming multidrug resistance in taxane chemotherapy.
Clinical chemistry and laboratory medicine, , Volume: 40, Issue:9		2002
Medicinal chemistry and chemical biology of new generation taxane antitumor agents.
IUBMB life, , Volume: 53, Issue:4-5
Oral efficacy and bioavailability of a novel taxane.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Volume: 6, Issue:5		2000
[Discovery and development of novel anticancer drug capecitabine].
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, , Volume: 119, Issue:12		1999

Dosage (28)

ArticleYear
[Role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) treatment: still standard or exception?]
Urologie (Heidelberg, Germany), , Volume: 62, Issue:12		2023
Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Jun-03, Volume: 31, Issue:6		2023
Exploring optimal Taxol® CYP725A4 activity in Saccharomyces cerevisiae.
Microbial cell factories, , Sep-19, Volume: 21, Issue:1		2022
Comparison of Autologous Breast Reconstruction Complications by Type of Neoadjuvant Chemotherapy Regimen.
Plastic and reconstructive surgery, , Dec-01, Volume: 148, Issue:6		2021
Role of TDM-based dose adjustments for taxane anticancer drugs.
British journal of clinical pharmacology, , Volume: 87, Issue:2		2021
Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients.
Neurophysiologie clinique = Clinical neurophysiology, , Volume: 50, Issue:1		2020
Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer.
JAMA oncology, , 02-01, Volume: 6, Issue:2		2020
A pilot study evaluating chemotherapy tolerability for breast cancer patients who have received prior treatment and chest radiation for Hodgkin Lymphoma.
Cancer treatment and research communications, , Volume: 15		2018
Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 26, Issue:9		2018
Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.
Pharmacogenetics and genomics, , Volume: 28, Issue:2		2018
Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418).
Oncotarget, , Jan-03, Volume: 8, Issue:1		2017
Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.
Theranostics, , Volume: 4, Issue:6		2014
Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
Pharmacogenomics, , Volume: 14, Issue:5		2013
Trastuzumab emtansine in breast cancer.
Expert opinion on biological therapy, , Volume: 13, Issue:4		2013
Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
Medical oncology (Northwood, London, England), , Volume: 30, Issue:1		2013
Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study.
Thrombosis research, , Volume: 130, Issue:6		2012
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Cancer chemotherapy and pharmacology, , Volume: 69, Issue:2		2012
Changes to adjuvant systemic therapy in breast cancer: a decade in review.
Clinical breast cancer, , Volume: 10, Issue:3		2010
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jun-20, Volume: 27, Issue:18		2009
Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer.
Investigational new drugs, , Volume: 26, Issue:4		2008
Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, , Volume: 9, Issue:7		2007
Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study.
Japanese journal of clinical oncology, , Volume: 36, Issue:10		2006
The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
The oncologist, , Volume: 11 Suppl 1		2006
A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
Gynecologic oncology, , Volume: 102, Issue:3		2006
[Effective salvage chemotherapy with S-1 alone in a patient with lung metastasis of breast cancer].
Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 32, Issue:13		2005
A novel one-step drug-loading procedure for water-soluble amphiphilic nanocarriers.
Pharmaceutical research, , Volume: 21, Issue:6		2004
Taxanes: an overview of the pharmacokinetics and pharmacodynamics.
Urology, , Volume: 54, Issue:6A Suppl		1999
Determination of paclitaxel and related taxanes in bulk drug and injectable dosage forms by reversed phase liquid chromatography.
Analytical chemistry, , Jun-01, Volume: 69, Issue:11		1997

Interactions (19)

ArticleYear
Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer.
Medicine, , Oct-07, Volume: 101, Issue:40		2022
A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer.
Clinical breast cancer, , Volume: 21, Issue:3		2021
Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
Breast cancer research and treatment, , Volume: 188, Issue:2		2021
A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer.
Breast cancer (Tokyo, Japan), , Volume: 27, Issue:2		2020
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
Annals of oncology : official journal of the European Society for Medical Oncology, , 05-01, Volume: 30, Issue:5		2019
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.
Annals of oncology : official journal of the European Society for Medical Oncology, , 12-01, Volume: 29, Issue:12		2018
Cancer Nanomedicines Stabilized by π-π Stacking between Heterodimeric Prodrugs Enable Exceptionally High Drug Loading Capacity and Safer Delivery of Drug Combinations.
Theranostics, , Volume: 7, Issue:15		2017
The efficacy and safety of endostar combined with taxane-based regimens for HER-2-negative metastatic breast cancer patients.
Oncotarget, , May-24, Volume: 7, Issue:21		2016
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 07-01, Volume: 34, Issue:19		2016
A Network-Based Target Overlap Score for Characterizing Drug Combinations: High Correlation with Cancer Clinical Trial Results.
PloS one, , Volume: 10, Issue:6		2015
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 25, Issue:8		2014
Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study.
Chinese medical journal, , Volume: 125, Issue:5		2012
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
The Lancet. Oncology, , Volume: 13, Issue:2		2012
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Health technology assessment (Winchester, England), , Volume: 15 Suppl 1		2011
Possible benefits of curcumin regimen in combination with taxane chemotherapy for hormone-refractory prostate cancer treatment.
Nutrition and cancer, , Volume: 62, Issue:2		2010
Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial.
Anticancer research, , Volume: 28, Issue:5B
Enhanced antitumor activity of irofulven in combination with antimitotic agents.
Investigational new drugs, , Volume: 20, Issue:3		2002
[Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung].
Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 29, Issue:1		2002
Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracyclin
British journal of cancer, , Sep-14, Volume: 85, Issue:6		2001